Next, oxidative stress maintains inflammation in the gut mucosa by activating redox-sensitive signaling pathways and transcription factors.[21] A clinical study found that infliximab, a tumor necrosis factor inhibitor, significantly reduced the circulating leukocytes and neutrophil counts in patients with IBD, thereby improving the intestinal inflammatory response of patients.[22] These findings will support the broader use of antineutrophilic therapy in the management of UC and IBD. Here, TNF is linked to inflammatory bowel disease.